MAP2K7 and melanoma: In just one example, the wide array of resistance mechanisms in BRAF-mutant melanoma to RAF inhibitors (RAFi) include mutations in NRAS, MEK and ERK and the amplification and alternative splicing of BRAF [20, 38–41].